surpass trial tirzepatide SURPASS-CVOT Shows Mounjaro Surpasses Trulicity in CV Outcomes

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

22.52

★★★★☆4.8 (126)

Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity

26.55

★★★★★4.9 (98)

Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice

28.42

★★★★★5.0 (157)

Tirzepatide Demonstrates Cardioprotective Effects in SURPASS-CVOT Trial

28.23

★★★★★4.7 (84)

In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%

28.40

★★★★★4.9 (203)

Effects of tirzepatide on adjudicated cardiovascular events in

20.87

★★★★★5.0 (176)

In patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to major cardiovascular events. ⁣, ⁣, Read the full SURPASS-CVOT

28.88

★★★★★4.8 (132)